Comprehensive genomic profiling of combined small cell lung cancer.
Jing Zhang, Liping Zhang, Jie Luo, Tao Ge, Pengyu Fan, Liangdong Sun, Likun Hou, Junqiang Li, Huansha Yu, Chunxiao Wu, Yuming Zhu, Chunyan Wu, Gening Jiang, Giancarlo Troncone, Jyoti Malhotra, Katsuhiro Okuda, Mariacarmela Santarpia, Rita Zamarchi, Taichiro Goto, Andrés F Cardona, Jianfang Xu, Qiankun Chen, Zhonghong Zhang, Peng Zhang, written on behalf of the AME Lung Cancer Collaborative Group
Translational lung cancer research 2021 FebCombined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC. The clinical and pathological characteristics of pure SCLC and CSCLC patients were analyzed. Immunohistochemistry and microdissection were performed to isolate the CSCLC components. Further molecular analysis was carried out by next-generation sequencing (NGS) in 12 CSCLC and 30 pure SCLC. There were no significant differences in clinical features between CSCLC and pure SCLC. Overall survival (OS) of CSCLC patients was worse than pure SCLC (P=0.005). NGS results indicated that TP53 and RB1 were the most frequently mutated genes in both CSCLC (83.33% and 66.67%) and pure SCLC (80.00% and 63.33%) groups. However, less than 10% common mutations were found in both CSCLC and pure SCLC. When analyzing the data of SCLC and non-small cell lung cancer (NSCLC) components of CSCLC, more than 50% common mutations, and identical genes with mutations were detected. Moreover, there were also common biological processes and signaling pathways identified in CSCLC and pure SCLC, in addition to SCLC and NSCLC components. There were no significant differences in terms of clinical features between CSCLC and pure SCLC. However, the prognosis for CSCLC was worse than pure SCLC. NGS analysis suggested that CSCLC components might derive from the same pluripotent single clone with common initial molecular alterations and subsequent acquisitions of other genetic mutations. 2021 Translational Lung Cancer Research. All rights reserved.
Citation
Jing Zhang, Liping Zhang, Jie Luo, Tao Ge, Pengyu Fan, Liangdong Sun, Likun Hou, Junqiang Li, Huansha Yu, Chunxiao Wu, Yuming Zhu, Chunyan Wu, Gening Jiang, Giancarlo Troncone, Jyoti Malhotra, Katsuhiro Okuda, Mariacarmela Santarpia, Rita Zamarchi, Taichiro Goto, Andrés F Cardona, Jianfang Xu, Qiankun Chen, Zhonghong Zhang, Peng Zhang, written on behalf of the AME Lung Cancer Collaborative Group. Comprehensive genomic profiling of combined small cell lung cancer. Translational lung cancer research. 2021 Feb;10(2):636-650
PMID: 33718010
View Full Text
